Effective

date

03/20/2000

03/20/2000

03/20/2000

03/20/2000

03/20/2000

03/20/2000

03/20/2000

03/20/2000

03/20/2000

03/20/2000

Subject, city, state	Effective date	Subject, city, state
FLOSSMOOR, IL		LUYANDO, DAVID JR
THACHENKERY, MARIA LEMONT. IL	03/20/2000	DOLTON, IL. NELSON, ROBERT L
THAWANI, RAM	03/20/2000	MACON, GA.
WILMETTE, IL		READ, ELIZABETH G
Fraud/Kickbacks		RALEIGH, NC. ROBINSON, KENNETH E
A K MEDICAR, INC	11/17/1999	AMERICUS, GA. SIDORE, STEVEN C
LINCOLNWOOD, IL EZRA MEDICAL TRANSPOR-		ROCHESTER, NY. SMYTHE, WILLIAM R
TATION	11/17/1999	MISSOURI CITY, TX.
LINCOLNWOOD, IL		SOMERVILLE, LAURIE A
GUTMAN, IRIT	11/17/1999	W PALM BEACH, FL.
LINCOLNWOOD, IL		WARRICK, DENNIS A
LUBINCSKIY, ILYIA	11/17/1999	ATLANTA, GA.
LINCOLNWOOD, IL		WATERMAN, ERNEST MARK
TAMID MEDICAL TRANS-	44/47/4000	CLAREMONT, CA.
PORT, INC	11/17/1999	WHITEHALL, WESLEY W
LINCOLNWOOD, IL		SAN DIEGO, CA.
Owned/Controlled by Convict	od/Evoludod	

Owned/Controlled by Convicted/Excluded

Owned/Controlled by Convicti	eu/Excludeu
A & J MEDICAL CORP	03/20/2000
HIALEAH, FL GENESIS MEDICAL, INC	03/20/2000
MIAMI, FL GRAMI CORPORATION, INC HIALEAH. FL	03/20/2000
GREEN EXPRESS MEDICAL	
EQUIP HIALEAH. FL	03/20/2000
HOME AWAY HOMELAKEWOOD, CO	03/20/2000
LOCK CHIROPRACTIC CEN-	
TER ROYERSFORD, PA	03/20/2000
RESOURCE MGMT GROUP OF S FL	03/20/2000
TUCKER, GA THERAPEUTIC INTERVEN-	
TIONS, INCVERSAILLES, MO	03/20/2000
WESTWOOD ORTHOPEDIC	
CO LOS ANGELES, CA	11/02/1999

Default on Heal Loan

Delaalt on rical Loan		
AYERS, STEPHEN C	03/20/2000	
LAKE CHARLES, LA. CHURCH, STEVEN D	11/19/1999	
MERIDEN, CT. COLE, PERRY J	03/20/2000	
JACKSONVILLE, FL. DOHERTY, PAUL J	03/20/2000	
ABINGTON, MA. EMERY, FRED B	03/20/2000	
TULSA, OK. ETZLER, RICHARD A	03/20/2000	
LOS ANGELES, CA. FELDMAN, STEPHEN J	03/20/2000	
SAINT LOUIS, MO. FIFIELD, FRED W	02/17/2000	
MODESTO, CA. FLOYD, REGINALD J	03/20/2000	
MONTGOMERY, AL. GODFREY, JOHN T	03/20/2000	
EDMOND, OK. GONZALES, DAVID L JR	03/20/2000	
S HOUSTON, TX. JOHNSON, DELILAH A	03/20/2000	
BON AQUA, TN.	03/20/2000	

Dated: February 6, 2000.

Ioanne Lanahan.

Director, Health Care Administrative Sanctions, Office of Inspector General. [FR Doc. 00–6742 Filed 3–17–00; 8:45 am] BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the Board of Scientific Counselors, National Cancer Institute.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(6) and 552b(c)(9)(B), Title 5 U.S.C., as amended. The discussions could reveal information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy and the premature disclosure of discussions related to personnel and programmatic issues would be likely to significantly frustrate the subsequent implementation of recommendations.

Name of Committee: Board of Scientific Counselors, National Cancer Institute,

Subcommittee A—Clincal Sciences and Epidemiology.

Date: March 22–23, 2000.

Closed: March 22, 2000, 7 pm to 10:15 pm. Agenda: Chairman's Remarks and Discussion of personnel and programmatic issues; Review and evaluation of individual Principal Investigators.

Place: Residence Inn by Marriott, Montgomery II, 7335 Wisconsin Ave., Bethesda, MD 20814.

Name of Committee: Board of Scientific Counselors, National Cancer Institute, Subcommittee B—Basic Sciences.

Date: March 22-23, 2000.

Closed: March 22, 2000, 7 pm to 9:50 pm. Agenda: Chairman's Remarks and Discussion of personnel and programmatic issues; Site visit Reports; Review and evaluation of individual Principal Investigators.

Place: Holiday Inn-Washington/Chevy Chase, Somerset Room, 5520 Wisconsin Ave., Chevy Chase, MD 20815.

Open: March 23, 2000, 8 am to 9:30 am. Agenda: Joint Session with Board of Scientific Counselors, National Cancer Institute, Subcommittee A—Clinical Sciences and Epidemiology and the National Cancer Institute, Board of Scientific Advisors Report of the Director, NCI.

Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C wing, 6th Floor, Conference Room 10, Bethesda, MD 20892.

Closed: March 23, 2000, 9:30 am to 10:30 am. Joint Meeting of the Board of Scientific Counselors, National Cancer Institute, Subcommittee A—Clincal Sciences and Epidemiology and Subcommittee B—Basic Sciences.

Agenda: To review and evaluate personal qualifications and performance and competence of individual investigators.

Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 6, Bethesda, MD 20892.

Name of Committee: Board of Scientific Counselors, National Cancer Institute, Subcommittee A— Clinical Sciences and Epidemiology.

Closed: March 23, 2000, 10:30 am to 4 pm. Agenda: To review and evaluate personal qualifications and performance and competence of individual investigators.

Place: Hyatt Regency Bethesda, Fellini's One Bethesda Metro Center, Bethesda, MD 20814.

Open: March 23, 2000, 4 pm to 4:45 pm. Agenda: Concept Review: Human papillomavirus type 16 vaccine trial in Costa Rica.

Place: Hyatt Regency Bethesda, Fellini's, One Bethesda Metro Center, Bethesda, MD 20814.

Contact Person: Abby Sandler, Executive Secretary, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 7019, Bethesda, MD 20892, (301) 496–7628.

Name of Committee: Board of Scientific Counselors, National Cancer Institute, Subcommittee B—Basic Sciences.

Closed: March 23, 2000, 10:30 am to 5:30 pm.

Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators.

Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Rooms 6 and 7, Bethesda, MD 20892.

Contact Person: Florence E. Farber, Executive Secretary, Institute Review Office; Office of the Director, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 7017, Bethesda, MD 20892, (301) 496–7628.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the intramural research review cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 9, 2000.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–6769 Filed 3–17–00; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Director's Challenge: Toward a Molecular Classification of Tumors.

Date: April 12–13 2000. Time: 8 am to 5 pm.

Agenda: To review and evaluate grant applications.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Ray Bramhall, Scientific Review Administrator, Special Review, Referral and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Suite 8060, Rockville, MD 20892, 301/594–1403.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health HHS)

Dated: March 10, 2000.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–6777 Filed 3–17–00; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group, Subcommittee A—Cancer Centers.

Date: April 10–11, 2000.

Time: 7:30 am to 4 pm. Agenda: To review and evaluate grant applications.

Place: Holiday Inn—Georgetown, 2101 Wisconsin Avenue, N.W., Washington, DC

Contact Person: David E. Maslow, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard—Room 8054, Bethesda, MD 20892–7405, 301/496–2330.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.395, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support, 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 10, 2000.

Anna Snouffer.

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 00–6778 Filed 3–17–00; 8:45 am] BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Initial Review Group, Subcommittee D—Clinical Studies.

Date: April 12–14, 2000. Time: 7:30 pm to 12 pm.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Contact Person: Martin H. Goldrosen, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8050, Rockville, MD 20852–7408, (301) 496–7930.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)